A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.

@article{Ardalan1991API,
  title={A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.},
  author={B Shoja Ardalan and Kasi S. Sridhar and Pasquale Benedetto and Stephen P. Richman and Stuart Waldman and Lauren Morrell and Lynn G. Feun and Niramol Savaraj and Magdolna Fodor and Alan Livingstone},
  journal={Cancer},
  year={1991},
  volume={68 6},
  pages={
          1242-6
        }
}
Twenty-eight patients with refractory advanced malignancies were treated with a 24-hour infusion of 5-fluorouracil (5-FU), leucovorin (LV), and N-(phosphonacetyl)-L-aspartic acid (PALA) weekly. Twenty-seven patients were evaluable to assess toxicity and antitumor activity. The PALA was administered as an intravenous bolus over 15 minutes at a fixed dose (250 mg/m2) 24 hours before the start of the 5-FU and leucovorin infusions. Initially the dose of 5-FU was 750 mg/m2; this was increased… CONTINUE READING
BETA